Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dinko Rekić

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|May 20, 2020
Assumption Checking Before Application of the Prespecified QT Linear Mixed Effect Model is EssentialDinko Rekić, Joanna Parkinson, Holly Kimko
Clinical Pharmacokinetics|September 20, 2020
Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of BodyweightDinko Rekić, Susanne Johansson, Jacob Leander
Journal of Pharmacokinetics and Pharmacodynamics|July 27, 2025
Practical guide to concentration-QTc modeling: a hands-on tutorialJoanna Parkinson, Corina Dota, Dinko Rekić
British Journal of Clinical Pharmacology|March 15, 2011
In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotypeDinko Rekić, Daniel Röshammar, Jackson Mukonzo, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 12, 2013
Model based design and analysis of phase II HIV-1 trialsDinko Rekić, Daniel Röshammar, Ulrika S H Simonsson
Toxicological Sciences : an Official Journal of the Society of Toxicology|January 22, 2011
Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccineLars Barregard, Dinko Rekić, Milena Horvat, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 17, 2021
A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseasesJacob Leander, Mikael Sunnåker, Dinko Rekić, et al.
Journal of Clinical Pharmacology|February 24, 2021
QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011-2019Sarit Cohen-Rabbie, Alienor C Berges, Dinko Rekić, et al.
Journal of Clinical Pharmacology|April 11, 2022
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes MellitusJohanna Melin, Weifeng Tang, Dinko Rekić, et al.
Annals of the American Thoracic Society|April 8, 2017
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary FibrosisMiya O Paterniti, Youwei Bi, Dinko Rekić, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
CPT: Pharmacometrics & Systems Pharmacology|May 20, 2020
Assumption Checking Before Application of the Prespecified QT Linear Mixed Effect Model is EssentialDinko Rekić, Joanna Parkinson, Holly Kimko
Clinical Pharmacokinetics|September 20, 2020
Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of BodyweightDinko Rekić, Susanne Johansson, Jacob Leander
Journal of Pharmacokinetics and Pharmacodynamics|July 27, 2025
Practical guide to concentration-QTc modeling: a hands-on tutorialJoanna Parkinson, Corina Dota, Dinko Rekić
British Journal of Clinical Pharmacology|March 15, 2011
In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotypeDinko Rekić, Daniel Röshammar, Jackson Mukonzo, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 12, 2013
Model based design and analysis of phase II HIV-1 trialsDinko Rekić, Daniel Röshammar, Ulrika S H Simonsson
Toxicological Sciences : an Official Journal of the Society of Toxicology|January 22, 2011
Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccineLars Barregard, Dinko Rekić, Milena Horvat, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 17, 2021
A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseasesJacob Leander, Mikael Sunnåker, Dinko Rekić, et al.
Journal of Clinical Pharmacology|February 24, 2021
QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011-2019Sarit Cohen-Rabbie, Alienor C Berges, Dinko Rekić, et al.
Journal of Clinical Pharmacology|April 11, 2022
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes MellitusJohanna Melin, Weifeng Tang, Dinko Rekić, et al.
Annals of the American Thoracic Society|April 8, 2017
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary FibrosisMiya O Paterniti, Youwei Bi, Dinko Rekić, et al.
Pageof 3